Outcomes of Tuberculosis Treatment and Contributing Factors Among Patients Receiving Anti-TB Therapy in Public Health Facilities of Nekemte, Oromia Region, Western Ethiopia - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Outcomes of Tuberculosis Treatment and Contributing Factors Among Patients Receiving Anti-TB Therapy in Public Health Facilities of Nekemte, Oromia Region, Western Ethiopia

  • By

  • Robsan Gudeta Getachew

  • Rut Oljira

  • Ayantu Getahun

  • Lemane Dereje

  • Milion Gebrewold Abdi

  • Tadesse Tolossa

  • December 30, 2025

Share

  • 1

    Tuberculosis is a major public health issue in Ethiopia, being the leading cause of morbidity and mortality in the country.

  • 2

    Ethiopia's national tuberculosis control program employs the DOTS strategy, achieving 100% geographic coverage in public health facilities.

  • 3

    The study analyzed treatment outcomes of 800 TB patients from Nekemte public health facilities over a four-year period.

  • 4

    Despite the implementation of effective treatment strategies, challenges remain in improving TB treatment outcomes in Ethiopia.

  • 5

    Evaluating treatment outcomes and identifying contributing factors are essential for enhancing TB management programs in Ethiopia.

Original Source(s)

Outcomes of Tuberculosis Treatment and Contributing Factors Among Patients Receiving Anti-TB Therapy in Public Health Facilities of Nekemte, Oromia Region, Western Ethiopia

  • by Robsan Gudeta Getachew, Rut Oljira, Ayantu Getahun, Lemane Dereje, Milion Gebrewold Abdi, Tadesse Tolossa

  • December 30, 2025

Related Content

Distribution of quorum-sensing genes (lasI, lasR, RhlI, and rhlR) among clinical isolates of biofilm-forming Pseudomonas aeruginosa in Northern Iran

Sugar may worsen antibiotic-induced gut dysbiosis

The effect was most apparent with added sugars and formulated nutritional drinks, including sports drinks and nutritional shakes.

Expert panel endorse individualized beta-lactam dosing for acutely ill patients

International guidance supports concentration-guided dosing for selected acutely ill patients, with clinical cure showing the clearest benefit.